Beam Therapeutics (BEAM) reported a Q4 loss Tuesday of $1.09 per diluted share, swinging from a profit of $1.73 a year earlier.
Analysts polled by FactSet expected a loss of $1.23.
License and collaboration revenue for the quarter ended Dec. 31 was $30.1 million, down from $316.2 million a year earlier.
Analysts surveyed by FactSet expected $17.2 million.
As of Dec. 31, 2024, cash, cash equivalents and marketable securities were $850.7 million, compared with $1.2 billion a year earlier.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。